Companies › Bio Meds Pharmaceutica Ltda
2 active drug programs in 2 registered trials: 2 Phase 4; Genitourinary; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Implantable gestrinone Progestin (synthetic steroid hormone) | – | Phase 4 | Endometriosis | Mar 2027 |
| Oral Dienogest Progestin (nortestosterone derivative) | – | Phase 4 | Endometriosis | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06543550 | Implantable gestrinone | Phase 4 | Endometriosis | Genitourinary | Mar 2027 |
| NCT06543550 | Oral Dienogest | Phase 4 | Endometriosis | Genitourinary | Mar 2027 |
No annotated target.
–
Vantive Health Fertility Center of Las Vegas Zydus Lifesciences Granata Bio Dimerix Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.